Yoshida S, Miyata M, Suzuki E, Kanno T, Sumichika Y, Saito K
J Clin Med. 2024; 13(10).
PMID: 38792541
PMC: 11122599.
DOI: 10.3390/jcm13103000.
Morand E, Merola J, Tanaka Y, Gladman D, Fleischmann R
Nat Rev Rheumatol. 2024; 20(4):232-240.
PMID: 38467779
DOI: 10.1038/s41584-024-01093-w.
Yoshida S, Miyata M, Suzuki E, Kanno T, Sumichika Y, Saito K
Front Immunol. 2023; 14:1267749.
PMID: 37868999
PMC: 10586060.
DOI: 10.3389/fimmu.2023.1267749.
Cummings J, Leisgang Osse A, Kinney J
Drugs. 2023; 83(15):1387-1408.
PMID: 37728864
PMC: 10582128.
DOI: 10.1007/s40265-023-01938-w.
Dadwal N, Kurmi B, Singh D, Singh A
Recent Pat Nanotechnol. 2023; 18(3):259-277.
PMID: 37264655
DOI: 10.2174/1872210517666230601124620.
JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences.
Ott N, Faletti L, Heeg M, Andreani V, Grimbacher B
J Clin Immunol. 2023; 43(6):1326-1359.
PMID: 37140667
PMC: 10354173.
DOI: 10.1007/s10875-023-01483-x.
Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases.
Levine A, Mark D, Smith L, Zheng H, Suskind D
Pharmaceutics. 2023; 15(3).
PMID: 36986830
PMC: 10059893.
DOI: 10.3390/pharmaceutics15030969.
CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production.
Gaur R, Mensah K, Stricker J, Adams M, Parton A, Cedzik D
Arthritis Res Ther. 2022; 24(1):199.
PMID: 35982464
PMC: 9386913.
DOI: 10.1186/s13075-022-02850-6.
An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases.
Luo T, Wang Y, Tang H, Zhou F, Chen Y, Pei B
J Inflamm Res. 2022; 15:3447-3466.
PMID: 35726215
PMC: 9206518.
DOI: 10.2147/JIR.S362732.
A Comprehensive Overview of Globally Approved JAK Inhibitors.
Shawky A, Almalki F, Abdalla A, Abdelazeem A, Gouda A
Pharmaceutics. 2022; 14(5).
PMID: 35631587
PMC: 9146299.
DOI: 10.3390/pharmaceutics14051001.
Validated DBS method for filgotinib quantitation in rat dried blood spots and its application to a pharmacokinetic study in rats.
Dixit A, Kiran V, Gabani B, Mullangi R
ADMET DMPK. 2022; 8(2):139-148.
PMID: 35300367
PMC: 8915582.
DOI: 10.5599/admet.796.
Downregulation of Renal Hsa-miR-127-3p Contributes to the Overactivation of Type I Interferon Signaling Pathway in the Kidney of Lupus Nephritis.
Wu L, Han X, Jiang X, Ding H, Qi C, Yin Z
Front Immunol. 2021; 12:747616.
PMID: 34745118
PMC: 8566726.
DOI: 10.3389/fimmu.2021.747616.
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
Friedman M, Curtis J, Winthrop K
Ann Rheum Dis. 2021; 80(10):1255-1265.
PMID: 34493491
PMC: 8494475.
DOI: 10.1136/annrheumdis-2021-221244.
Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage.
Reddig A, Voss L, Guttek K, Roggenbuck D, Feist E, Reinhold D
J Clin Med. 2021; 10(7).
PMID: 33916057
PMC: 8036268.
DOI: 10.3390/jcm10071431.
Dose Reduction of Tumor Necrosis Factor Inhibitor and its Effect on Medical Costs for Patients with Ankylosing Spondylitis.
Koo B, Lim Y, Lee M, Jeon J, Yoo H, Oh I
Rheumatol Ther. 2021; 8(1):347-359.
PMID: 33420967
PMC: 7991020.
DOI: 10.1007/s40744-020-00274-9.
The Role of Cutaneous Type I IFNs in Autoimmune and Autoinflammatory Diseases.
Turnier J, Kahlenberg J
J Immunol. 2020; 205(11):2941-2950.
PMID: 33229366
PMC: 7694882.
DOI: 10.4049/jimmunol.2000596.
IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.
Li H, Tsokos G
Clin Rev Allergy Immunol. 2020; 60(1):31-45.
PMID: 33185790
PMC: 8018566.
DOI: 10.1007/s12016-020-08823-4.
Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation.
Buxbaum N, Pavletic S
Front Immunol. 2020; 11:2017.
PMID: 32983144
PMC: 7479824.
DOI: 10.3389/fimmu.2020.02017.
Promising and Upcoming Treatments in Myositis.
Smith L, Paik J
Curr Rheumatol Rep. 2020; 22(10):65.
PMID: 32845402
PMC: 7955788.
DOI: 10.1007/s11926-020-00943-2.
Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19.
Massalska M, Maslinski W, Ciechomska M
Cells. 2020; 9(8).
PMID: 32796683
PMC: 7464410.
DOI: 10.3390/cells9081876.
